Ruxolitinib S enantiomer (INCB18424) is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective JAK1/2 inhibitor.
More Information Supplier Page
Remodelin HBr salt is a novel potent and selective inhibitor of the acetyl-transferase protein NAT10.
More Information Supplier Page
Remodelin HBr salt is a novel potent and selective inhibitor of the acetyl-transferase protein NAT10.
More Information Supplier Page Remodelin HBr salt is a novel potent and selective inhibitor of the acetyl-transferase protein NAT10.
More Information Supplier Page 
Probucol is an anti-hyperlipidemic drug initially developed in the treatment of coronary artery disease by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism.
More Information Supplier Page
Probucol is an anti-hyperlipidemic drug initially developed in the treatment of coronary artery disease by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism.
More Information Supplier Page Probucol is an anti-hyperlipidemic drug initially developed in the treatment of coronary artery disease by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism.
More Information Supplier Page Probucol is an anti-hyperlipidemic drug initially developed in the treatment of coronary artery disease by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism.
More Information Supplier Page Probucol is an anti-hyperlipidemic drug initially developed in the treatment of coronary artery disease by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism.
More Information Supplier Page 
